



Research gaps in viral hepatitis

Anders Boyd, Léa Duchesne, Karine Lacombe

► To cite this version:

Anders Boyd, Léa Duchesne, Karine Lacombe. Research gaps in viral hepatitis. Journal of the International AIDS Society, 2018, 21, pp.e25054. 10.1002/jia2.25054 . hal-02297926

HAL Id: hal-02297926

<https://hal.sorbonne-universite.fr/hal-02297926>

Submitted on 26 Sep 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

COMMENTARY

Research gaps in viral hepatitis

Anders Boyd^{1,2}, Léa Duchesne¹ and Karine Lacombe^{3,4§}

§Corresponding author: Karine Lacombe, Service de Maladies Infectieuses, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75012 Paris, France. Tel: +33 1 49 28 24 38. (karine.lacombe2@aphp.fr)

Abstract

Introduction: The World Health Organization has aimed for global elimination of both hepatitis B virus (HBV) and hepatitis C virus (HCV) by 2030. Treatments available to cure HCV and control HBV, as well as vaccination to prevent HBV infection, have certainly allowed for such bold goals, yet the final steps to usher in elimination require further evidence.

Discussion: We broadly discuss the needs for three major public health approaches. First, an effective vaccine exists for HBV and mass-vaccination campaigns have resulted in decreases in hepatitis B surface antigen seroprevalence and overall rates of liver-related mortality. Still, HBV vaccination coverage is poor in certain regions of the world, while the reasons for such low coverage require further study. A prophylactic vaccine is probably needed to eliminate HCV, but is not being readily developed. Second, identifying HBV/HCV infected individuals remains a priority to increase awareness of disease status, particularly for key populations. Research evaluating large-scale implementation of novel, rapid and mobile point-of-care tests would be helpful to determine whether increased awareness is achievable in these settings. Third, antiviral therapy allows for strong HBV suppression and HCV cure, while its access depends on financial factors among many others. Although there is strong evidence to treat key populations and specific groups with progressed disease, as stated in current guidelines, the advantages of extending treatment eligibility to decrease onward spread of HBV/HCV infection and prevent further burden of disease are lacking “real world” evidence. Novel anti-HBV treatments are being developed to target intrahepatocellular HBV replication, but are still in the early phases of clinical development. Each of the strategies mentioned above has specific implications for HIV infection.

Conclusions: There are certainly effective tools to combat the spread of viral hepatitis and treat infected individuals – yet how they are able to reach key populations, and the infrastructure required to do so, continue to represent the largest research gap when evaluating the progress towards elimination. Continuously adapted and informed research is required to establish the priorities in achieving elimination goals.

Keywords: hepatitis B virus; hepatitis C virus; public health; testing; antivirals; eradication

Received 1 October 2017; Accepted 20 December 2017; Published 9 April 2018

Copyright © 2018 The Authors. *Journal of the International AIDS Society* published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

The 2015 update of the Global Burden of Diseases study has ranked chronic viral hepatitis and its underlying conditions, such as cirrhosis and liver cancer, among the top 20 causes of death, steeply increasing from 1990 to 2015 [1]. Nevertheless, an extensive array of tools is available to combat hepatitis B virus (HBV) and hepatitis C virus (HCV). HBV vaccination is effective at preventing infection. Individuals with chronic HBV-infection are able to reduce circulating HBV with almost no risk of developing resistance when using the potent nucleoside/nucleotide analogues (NA) entecavir, tenofovir disoproxil fumarate (TDF), or the more recent tenofovir alafenamide [2]. Novel direct-acting antivirals (DAAs) have allowed for short-term and effective treatment against HCV and are known to induce high rates of sustained virological response (SVR) [3].

With these effective means at hand, the World Health Organization (WHO) has aimed to achieve global elimination

of both infections by 2030. However, elimination implies strengthening existing tools – more efficient screening policies, wider access to care and management of liver disease, and antiviral agents that ultimately halt the virus. In this commentary, we broadly highlight some recent advances, and room for improvement, in three public health strategies geared towards HBV and HCV elimination that also include HIV coinfecting individuals: vaccination, testing and treatment.

2 | DISCUSSION

2.1 | Preventing ongoing transmission

With an effective HBV vaccine, many large-scale vaccination campaigns have been able to dramatically change the spectrum of liver-associated disease. For instance, widespread vaccination in China has led to substantial decreases in incident HBV infections and the prevalence of hepatitis B surface antigen (HBsAg)-positive serology [4]. Moreover, recent data from

Taiwan have confirmed that immunization in infants reduces the risk of hepatocellular carcinoma (HCC) during adulthood [5]. Worldwide three-dose HBV vaccine coverage has increased to 84% [6], yet a considerable proportion of the global population could still benefit from vaccination [7]. Understanding the logistic, financial, and cultural constraints to vaccine access would help further the use of this highly-effective, preventative measure.

Timely birth-dose vaccination (<24 hours after birth) among infants born to HBsAg-positive mothers has shown to prevent mother-to-child transmission. Birth-dose coverage is unfortunately lagging at <40% for many countries, with the lowest coverage in Africa at 10% [6]. As one-fifth of infants vaccinated at birth and born to hepatitis B “e” antigen (HBeAg) positive mothers become infected [8], this strategy requires further improvement. Treating highly viraemic mothers with TDF has been explored as a strategy to decrease transmission rates. However, these studies have been limited to mostly Asia [9] and further evaluation is needed in other regions with higher liver disease burden, such as Africa.

No prophylactic vaccine is available for HCV infection, while the virus’ genetic variability and capacity to escape host immune responses make vaccine development a formidable challenge [10,11]. Recent findings on the viral envelope structure and innovative experimental animal models have uncovered new opportunities for HCV vaccine research [12]. Nevertheless, there is ongoing debate whether HCV vaccination would even be useful towards elimination. Significant reduction in HCV incidence could be incurred from widespread access to DAA in key populations [13], yet this “treatment-as-prevention” (TasP) approach has only been evaluated with models strongly dependent on HCV baseline prevalence, treatment coverage, transmission network structure, harm reduction uptake and post-treatment changes in behaviour [14,15]. “Real-world” evaluations could test the accuracy of these assumptions. Models of TasP have also demonstrated cost-effectiveness among key populations [16]. It remains unknown if TasP is still cost-effective for other countries, especially those without voluntary licence agreements, where current DAA prices are prohibitive. Existing models have indicated that a vaccine, even if partially effective, could reduce HCV incidence at a lower cost than TasP [17,18] and without requiring specialized care.

2.2 | Identifying undiagnosed infection

2.2.1 | Infection unawareness

A targeted testing approach is not explicitly recommended for HBV [19], with the broad exception of testing all those “who do not know their status” [6], but is recommended for HCV based on risk or birth cohort [20]. HIV infection is also identified as a risk factor due to shared routes of transmission [21,22]. With this in mind, the 2017 WHO Global Hepatitis Report estimated that an alarming 91% of HBsAg-positive and 80% of HCV-positive individuals were unaware of their infection [6]. These estimates are considerably higher than the roughly 30% of HIV-infected individuals unaware of their infection [23]. Most undiagnosed cases of HBV and HCV in high-income countries (HIC) belong to marginalized groups not covered by conventional screening programmes [20].

Undiagnosed cases in low- to middle-income countries (LMIC) are also found in these key populations, but the greater problem lies in limited centralized diagnostic facilities, cost of testing, lacking public education and awareness, and need for skilled health professionals [24,25]. Improving general understanding of viral hepatitis and its health consequences are also central to increasing disease awareness and could be addressed via public health campaigns [26].

2.2.2 | Novel rapid-testing techniques

Despite the paucity of studies in LMIC, data support the cost-effectiveness of HBV testing in key populations (i.e. migrants) for HIC and in general for low-income countries with high HBsAg-positive seroprevalence [7]. Developing easy to use and affordable screening tools would allow a considerable scale-up in testing. Transportable in size and straightforward in use, point-of-care (POC) systems could widen testing availability and specificity have been validated in both HIC and LMIC [27]. Anti-hepatitis B surface and anti-hepatitis B core antibody status are also needed to determine HBV infection phase; however, rapid tests detecting these antibodies are either lacking or inadequate [27,28].

PCR is the gold standard approach to evaluate viral replication. HCV RNA and HBV-DNA are not often assessed due to high costs, heavy burden in human resources, which then restrains their availability [7]. Some less-costly molecular assays that could be easier to implement in LMIC are being developed, including a new semi-quantitative real-time PCR approach able to discriminate samples with HBV DNA levels above or below the clinically-relevant threshold of 2000 IU/ml [29]. However, field validation must be performed before concluding their usefulness in resource-limited settings. POC assays could extend viral load testing and increase those aware of having active HCV-infection. The stringent technical requirements to quantify HCV RNA offer little leeway for an inexpensive, portable POC test that must also be resistant to extreme environmental conditions and have a turnaround time of <1 hour. Systems have been developed, such as GeneXpert and Genedrive, that are able to accurately quantify HCV RNA and HBV-DNA [30,31], but the high cost of performing these assays limits its immediate appeal for LMIC. Other novel POCs targeting alternative markers of viraemic activity, such as Daktari and HCV core antigen detection [32], may pave the way for more affordable HCV POC tests. Next generation, microchip-sized diagnostics have been emerging in which innovations in nanotechnology, bioengineering and microfluid dynamics are combined [33]. Mobile tests using this technology could provide the low-cost, accuracy, and fully-automated features required for POC assays, yet are still in the early stages of development. In order to incorporate any of these diagnostic tools in screening guidelines, more comprehensive data on their accuracy, feasibility, acceptability and cost-effectiveness would be needed.

2.3 | Implications of antiviral therapy

2.3.1 | Need for antiviral treatment

The principle goal of NA treatment is suppressing HBV DNA to a level that is associated with reduced rates of liver-related

morbidity and mortality. Each phase of chronic HBV-infection is associated with a varying degree of viral activity and risk of severe clinical outcomes. Accordingly, HBeAg-positive or -negative chronic hepatitis B patients or those with compensate or decompensate cirrhosis are strongly recommended to initiate treatment [2]. For other phases of infection, there is still debate on when to initiate treatment. Patients early on in infection (i.e. HBeAg-positive chronic HBV infection) occasionally exhibit mild-to-severe liver fibrosis with highly active anti-HBV T-cell responses [34] and thus could benefit from early treatment. Other factors also drive the decision to treat, such as family risk of HCC (at high risk of disease) and older age (more willing to adhere to lifelong therapy) [35]. In addition, certain patients (i.e. HBV mono-infected individuals in sub-Saharan Africa) are oftentimes not recommended for treatment based on most guidelines, but demonstrate increased risk of HCC [36]. TDF-containing antiretroviral therapy should be initiated as early as possible for all HIV-HBV co-infected patients [37,38]. Despite these recommendations, there is a dearth of clear, large-scale evidence that delaying therapy affects HCC incidence or liver-related mortality in these subgroups [35].

EASL practice guidelines have recently incorporated a section on stopping treatment [2], yet criteria for discontinuation remain rather ambiguous. It should be stressed that this practice is highly discouraged for HIV-HBV co-infected patients due to its association with severe clinical outcomes [39,40]. In brief, patients should discontinue treatment if they have sustained HBsAg-loss. Treatment could be discontinued in (i) HBeAg-positive chronic HBV patients who achieved HBeAg-seroconversion, undetectable HBV-DNA and normalized transaminases and underwent at least 12 months of consolidation therapy, and to a lesser extent, (ii) HBeAg-negative patients with at least 3 years of virological suppression. Since these latter two groups have variable rates of virological and clinical relapse, close virological monitoring is strongly encouraged. Predicting those at risk of failing discontinuation is difficult considering that no available marker has the capacity to do so, with the possible exception of very low HBsAg titres [41]. Whether other biomarkers, such as circulating HBV RNAs, could address, this issue remains speculative.

HCV treatment aims to cure infection and prevent further HCV-associated complications. The most recent EASL guidelines recommend broadening access to DAA treatment, focusing on HCV-infected individuals with significant fibrosis/cirrhosis, extrahepatic manifestations, HCV recurrence after liver transplantation, and risk of further transmission [3]. These guidelines are applied similarly to HIV-HCV co-infected patients, yet special consideration should be given to drug-drug interactions with other antiretroviral agents. Given the high SVR rates achieved with current regimens, there is strong advocacy for treating all HCV-infected individuals. However, the cost burden of effective DAAs, especially for single-payer healthcare systems, and its distribution remain obstacles for universal treatment [42].

Systematic reviews are available in which the distribution of HBV phases and HCV genotypes are provided worldwide [43,44]. Since recommendations for treatment initiation vary slightly between European, American, and Pacific liver associations, as well as WHO, applying epidemiological data to estimate the number of individuals needing treatment, and of

them who is receiving treatment, is not straightforward. In fact, the WHO Global Hepatitis Report assesses the treatment gap for HBV as “unknown” while for HCV, it considers that all infected patients are in need of treatment [6]. A more nuanced understanding of this step in the cascade-of-care is necessary.

2.3.2 | Novel treatments for chronic hepatitis B

With the success of DAA and along the lines of programmes aimed at HIV cure, there has been substantial momentum in developing therapeutic regimens to cure HBV [45]. The major impediment to such a goal is the eradication of covalently-closed circular DNA (ccc-DNA), the template used to transcribe all viral proteins, which cannot be achieved with current NAs [46]. Given that NAs only inhibit DNA polymerase activity, agents targeting other steps in the replication cycle are needed to further suppress intrahepatic replication. Development is underway of agents involved in blocking HBV entry via the sodium taurocholate co-transporting polypeptide cell receptor (myristoylated pre-S peptides, cyclophilin inhibitors), inhibiting gene expression at the mRNA level (short interfering RNAs), affecting core protein assembly (core protein allosteric modulators), and others (reviewed in [47]). These agents are still in the early clinical trial phases and have yet to be assessed in HIV-HBV co-infected patients.

HBV infection is known to exert a wide range of immunological deficiencies, including, but certainly not limited to, depletion of virus-specific cytotoxic T lymphocytes and increased T cell exhaustion [48]. There is then active interest in developing agents that elicit or restore antiviral immunity. Current therapeutic strategies have been engineered to affect both innate (toll-like receptor agonists) and adaptive (checkpoint inhibitors) arms of the immune system, but again are mostly experimental [47]. Considering that these approaches may require a highly orchestrated immune response, as is the case with interferon-based therapies [49], their efficacy could be reduced in immunocompromised HIV-HBV co-infected patients [50].

2.3.3 | Antiviral-induced virological response and clinical outcomes

Concomitant reductions in HCC incidence are generally observed with effective HBV suppression from NA-based therapy, yet this risk is not completely abrogated [51]. A low proportion of treated individuals with adequate viral suppression do develop HCC during treatment, questioning the adequacy of current antiviral agents. HBV DNA viral loads or quantitative HBsAg are also poor predictors of these events and perhaps other replicative biomarkers could more accurately establish disease risk [52]. Likewise, decreases in incident HCC have been observed in HIV-HBV co-infected patients over the past decade [53] as use of more potent anti-HBV agents has increased, yet the implications of suppressed HBV DNA is unclear [54].

There are conflicting results on the risk of developing HCC after DAA-induced SVR, with some studies reporting a higher HCC incidence rate [55,56] and others, including a meta-analysis, finding no or even a reduced rate [57-59]. Compensated cirrhosis is a well-known prognostic factor for HCC [60].

Recent research on HCV-induced epigenetic and transcriptional changes could further elucidate the mechanisms of developing HCC [61], but still require further study. Similarly, the consequences of HCV eradication on extrahepatic manifestations, such as diabetes or cardiovascular diseases, also need clarification. Data on DAA use and HCC incidence are starting to emerge in HIV-HCV co-infected patients and suggest that the risk of HCC may not be higher after HCV cure [62]. Previous data from the pegylated-interferon era have also suggested that co-infected patients are not privy to HCC after SVR [63].

2.3.4 | Access to treatment for infected populations

Scaling-up access to antiviral therapy has slowly begun in recent years with price negotiations, generic formulations, and localized production [6,64]. Still, potent anti-HBV treatments, such as TDF, are limited to HIV-HBV co-infected patients in Sub-Saharan Africa [24] or is not provided for more than a given amount of time. Cost of anti-HCV treatments has been greatly reduced, allowing for more widespread access, but continue to pose financial burdens for some LMIC [65].

Severe clinical outcomes in individuals infected with viral hepatitis cannot, however, be reduced by treatment alone, but will require effective healthcare services. Many barriers in accessing these services currently exist [66], with many more studies on HCV than HBV-infection [67]. First, prioritization of distributing and reimbursing NAs and DAAs are based on constrained resources or little empirical evidence for some countries [6,68,69]. Future research must aim to understand the epidemic of viral hepatitis, its disease progression and impact on quality of life in order to substantiate evidenced-based policies. Second, some countries only allow specialists to prescribe DAAs, while many key populations have difficulty in accessing these services. Integrating HCV testing in healthcare services reaching key populations (HIV clinics, harm reduction, in-prison services) and permitting community nurses or primary healthcare services to provide DAAs have shown increases in linkage to and retention in care [70–72]. However, the impact of such strategies in other settings is potentially offset by other systemic and individual barriers. Negative perceptions of HCV treatment, penalization and stigmatization of drug use and, in some countries, sexual preferences are all social factors discouraging key populations from consulting healthcare services [7]. Third, practitioners may be reluctant to treat individuals at high-risk of reinfection. Rates of reinfection among persons who inject drugs are rather variable, but are mostly lower when enrolled in harm-reduction programmes [73]. Nevertheless, harm reduction services might not reach non-opioid dependent persons and persons who formerly injected drugs, representing a major reservoir of infection [74]. High reinfection incidence has been observed in HIV-positive men who have sex with men, while the behavioural data to corroborate ongoing sexual risk behaviours as the underlying reason for this finding are scarce [75]. Specific post-treatment interventions aimed at reducing HCV re-infected are strongly needed. Finally, few countries have established a national viral hepatitis plan [76], making it difficult to guide clinicians on the most appropriate line of care.

3 | CONCLUSIONS

Notwithstanding the tools able to successfully prevent, suppress, and cure viral hepatitis, the most efficient way of their use requires considerable research. In the short-term, HBV vaccine coverage should be increased to all regions of the world, while the reasons for reluctance to vaccinate could provide insights on accomplishing this goal. Cheaper and easier technology to test for viral hepatitis should be developed and used in campaigns to increase infection awareness in key populations. Treatment must be accessible to infected individuals to prevent disease progression. Finally, it is likely that a combination of these tools is required for elimination of viral hepatitis [7,77]. Although the WHO Global Hepatitis Report has clearly laid out the needs at each step of the viral hepatitis cascade-of-care, continuous and informed research could help prioritize these shifting needs for policy makers and stakeholders alike.

AUTHORS' AFFILIATIONS

¹INSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; ²Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Netherlands; ³Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, AP-HP, Paris, France; ⁴Sorbonne Universités, INSERM, UPMC Univ Paris 06, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France

COMPETING INTERESTS

AB has received research grants from the Agence nationale de recherche sur le sida et les hépatites virales (ANRS), SIDACTION, and personal fees from Gilead Sciences, Inc. LD has no conflict of interest to declare. KL has received research grants from the ANRS and SIDACTION; personal fees and non-financial support from Gilead Sciences, Inc; personal fees and non-financial support from Abbvie; personal fees from Janssen; grants, personal fees and non-financial support from MSD.

AUTHORS' CONTRIBUTIONS

AB and LD drafted the manuscript. KL gave critical revisions. All authors approved the final version of this manuscript.

FUNDING

The authors report no funding in relation to the present commentary.

REFERENCES

1. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390(10100):1151–210.
2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;67(2):370–98.
3. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. *J Hepatol*. 2017;66(1):153–94.
4. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Reprint of: epidemiological serosurvey of Hepatitis B in China—declining HBV prevalence due to Hepatitis B vaccination. *Vaccine*. 2013;2731 Suppl 9:J21–8.
5. Chang M-H, You S-L, Chen C-J, Liu C-J, Lai M-W, Wu T-C, et al. Long-term effects of hepatitis B immunization of infants in preventing liver cancer. *Gastroenterology*. 2016;151(3):472–80.e1.
6. World Health Organization. Global hepatitis report, 2017 [Internet] [cited 17 December 2017]. Available from: <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/>

7. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis.* **2016**;16(12):1399–408.
8. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. *Cochrane Database of Systematic Reviews.* **2006**, Issue 2. Art. No.: CD004790. DOI:10.1002/14651858.CD004790.pub2.
9. Hyun MH, Lee Y-S, Kim JH, Je JH, Yoo YJ, Yeon JE, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. *Aliment Pharmacol Ther.* **2017**;45(12):1493–505.
10. Echeverría N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. *World J Hepatol.* **2015**;7(6):831–45.
11. Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. Hepatitis C virus–T-cell responses and viral escape mutations. *Eur J Immunol.* **2012**;42(1):17–26.
12. Fauvelle C, Colpitts CC, Keck Z-Y, Pierce BG, Fong SKH, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. *Expert Rev Vaccines.* **2016**;15(12):1535–44.
13. Martin NK, Vickerman P, Dore G, Hickman M. The HCV epidemics in key populations (including PWID, prisoners, and MSM): the use of DAAs as treatment for prevention. *Curr Opin HIV AIDS.* **2015**;10(5):374–80.
14. Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. *Lancet Infect Dis.* **2017**; DOI: 10.1016/S1473-3099(17)30676-X.
15. Metz C, Surey J, Francis M, Conneely J, Abubakar I, White PJ. Impact of hepatitis C treatment as prevention for people who inject drugs is sensitive to contact network structure. *Sci Rep.* **2017**;7:1833.
16. Leask JD, Dillon JF. Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. *Aliment Pharmacol Ther.* **2016**;44(2):145–56.
17. Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. *BMC Med.* **2015**;20(13):198.
18. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, et al. The potential impact of a hepatitis C vaccine for people who inject drugs: is a vaccine needed in the age of direct-acting antivirals? *PLoS ONE.* **2016**;11(5):e0156213.
19. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [cited 17 December 2017]. Available from: <http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/>
20. Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB. Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there? *J Int AIDS Soc.* **2017**;20(1):22146.
21. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. *Lancet Infect Dis.* **2016**;16(7):797–808.
22. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multi-stage systematic review. *Lancet Glob Health.* **2017**;5(12):e1192–207.
23. World Health Organization. HIV/AIDS [Internet] [cited 17 December 2017]. Available from: <http://www.who.int/mediacentre/factsheets/fs360/en/>
24. Lemoine M, Eholié S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. *J Hepatol.* **2015**;62(2):469–76.
25. Reipold EI, Trianni A, Krakower D, Ongarello S, Roberts T, Easterbrook P, et al. Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. *BMC Infect Dis.* **2017**;17 Suppl 1:702.
26. Shimakawa Y, Pourette D, Bainilago L, Enel C, Sombié R, Rado R, et al. Improving communication about viral hepatitis in Africa. *Lancet Infect Dis.* **2017**;17(7):688–9.
27. Bottero J, Boyd A, Gozlan J, Lemoine M, Carrat F, Collignon A, et al. Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort. *France J Hepatol.* **2013**;58(3):473–8.
28. Bottero J, Boyd A, Gozlan J, Carrat F, Lemoine M, Rougier H, et al. Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. *Eur J Gastroenterol Hepatol.* **2016**;28(6):633–9.
29. Castéra-Guy J, Rubbo P-A, Kania D, Lemoine M, Van de Perre P, Tuillon E. Semi-quantitative real-time PCR: a useful approach to identify persons with low replicative chronic hepatitis B. *J Virol Methods.* **2017**;244:1–3.
30. Gupta E, Agarwala P, Kumar G, Maiwall R, Sarin SK. Point-of-care testing (POCT) in molecular diagnostics: performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. *J Clin Virol.* **2017**;88:46–51.
31. Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan T-P, Firth R, et al. Clinical validation of a rapid point of need HCV molecular test. *J Hepatol.* **2017**;66(1):S98.
32. World Health Organization. Guidelines on hepatitis B and C testing [cited 17 December 2017]. Available from: <http://www.who.int/hepatitis/publications/guidelines-hepatitis-c-b-testing/en/>
33. Duchesne L, Lacombe K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. *J Viral Hepat.* **2017**; doi: 10.1111/jvh.12827.
34. Kennedy P, Litwin S, Dolman G, Bertolotti A, Mason W. Immune tolerant chronic hepatitis B: the unrecognized risks. *Viruses.* **2017**;9(5):96.
35. Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. *Gut.* **2012**;61(3):333–6.
36. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia. *Gut.* **2016**;65(12):2007–16.
37. Kouamé G-M, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, et al. Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication. *Clin Infect Dis.* **2018**;66(1):112–20.
38. European AIDS Clinical Society. EACS Guidelines [cited 17 December 2017]. Available from: <http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>
39. Boyd A, Houghtaling L, Moh R, Chekaraou MA, Gabillard D, Eholié SP, et al. Clinical outcomes during treatment interruptions in human immunodeficiency virus-hepatitis B virus co-infected patients from Sub-Saharan Africa. *Am J Trop Med Hyg.* **2017**;97(6):1936–42.
40. Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. *Clin Infect Dis.* **2008**;47(11):1468–75.
41. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int.* **2016**;10(1):1–98.
42. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. *PLoS Med.* **2016**;13(5):e1002032.
43. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology.* **2015**;61(1):77–87.
44. Ott JJ, Horn J, Krause G, Mikolajczyk RT. Time trends of chronic HBV infection over prior decades – a global analysis. *J Hepatol.* **2017**;66(1):48–54.
45. Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. *Gut.* **2015**;64(8):1314–26.
46. Boyd A, Lacombe K, Lavocat F, Maylin S, Mialhes P, Lascoux-Combe C, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. *J Hepatol.* **2016**;65(4):683–91.
47. Testoni B, Durantel D, Zoulim F. Novel targets for hepatitis B virus therapy. *Liver Int.* **2017**;37 Suppl 1:33–9.
48. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. *Nat Rev Immunol.* **2012**;12(3):201–13.
49. Kao J-H. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? *Liver Int.* **2014**;34 Suppl 1:112–9.
50. Boyd A, Piroth L, Maylin S, Maynard-Muet M, Leboussé F, Bouix C, et al. Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients. *J Viral Hepat.* **2016**;23(12):1017–26.
51. Papatheodoridis GV, Chan HL-Y, Hansen BE, Janssen HLA, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. *J Hepatol.* **2015**;62(4):956–67.
52. Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. *World J Gastroenterol.* **2016**;22(37):8271–82.
53. Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. *J Hepatol.* **2017**;66(2):297–303.
54. Boyd A, Lacombe K, Girard P-M. An improved understanding of severe liver morbidity in HIV-infected individuals. *AIDS.* **2016**;30(11):1843–5.
55. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. *J Hepatol.* **2016**;65(4):719–26.

56. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol*. **2016**;65(4):727–33.
57. The AN. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. *J Hepatol*. **2016**;65(4):734–40.
58. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analysis, and meta-regression. *J Hepatol*. **2017**;67(6):1204–12.
59. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. *J Hepatol*. **2018**;68(1):25–32.
60. European Association for the Study of the Liver. Clinical Practice Guidelines Management of Hepatocellular [cited 17 December 2017]. Available from: <http://www.easl.eu/research/our-contributions/clinical-practice-guidelines/detail/management-of-hepatocellular-carcinoma-easl-eortc-clinical-practice-guidelines/report/3>
61. Jühling F, Bandiera S, Hamdane N, Thumann C, Durand SC, Saghire HE, et al. Hepatitis C virus-induced epigenetic and transcriptional changes persist post cure. *J Hepatol*. **2017**;66(1):S21.
62. Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, et al. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/HCV-coinfected patients. *AIDS*. **2018**; in press.
63. Merchante N, Merino E, Rodríguez-Arrondo F, Tural C, Muñoz J, Delgado-Fernández M, et al. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. *AIDS*. **2014**;28(1):41–7.
64. Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. *J Virus Erad*. **2016**;2(1):28–31.
65. Assefa Y, Hill PS, Ulikpan A, Williams OD. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness? *Glob Health*. **2017**;13(1):73.
66. Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: structural barriers and public health potential. *Int J Drug Policy*. **2015**;26(11):1056–63.
67. Zhou K, Fitzpatrick T, Walsh N, Kim JY, Chou R, Lackey M, et al. Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. *Lancet Infect Dis*. **2016**;16(12):1409–22.
68. Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. *Lancet Gastroenterol Hepatol*. **2017**; DOI:10.1016/S2468-1253(17)30284-4.
69. Martin NK, Vickerman P, Hickman M. How to eliminate HCV infection by antiviral treatment. *J Hepatol*. **2017**;67(1):5–6.
70. Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of community based hepatitis C treatment. *BMC Infect Dis*. **2016**;16:202.
71. Radley A, Tait J, Dillon JF. DOT-C: a cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. *Int J Drug Policy*. **2017**;47:126–36.
72. Bruggmann P, Litwin AH. Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. *Clin Infect Dis*. **2013**;57 Suppl 2:S56–61.
73. Grebely J, Hajarizadeh B, Dore GJ. Direct-acting antiviral agents for HCV infection affecting people who inject drugs. *Nat Rev Gastroenterol Hepatol*. **2017**;14(11):641–51.
74. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet*. **2011**;378(9791):571–83.
75. Martinello M, Hajarizadeh B, Grebely J, Dore GJ, Matthews GV. HCV cure and reinfection among people with HIV/HCV coinfection and people who inject drugs. *Curr HIV/AIDS Rep*. **2017**;14(3):110–21.
76. World Health Organization. Global policy report on the prevention and control of viral hepatitis [cited 17 December 2017]. Available from: http://www.who.int/hiv/pub/hepatitis/global_report/en/
77. Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. *Clin Microbiol Infect*. **2016**;22(10):833–8.